louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00616096: Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels
Official title: Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dermatitis, Atopic
Keywords: Serum Immunoglobulin E above 5000 kU/l
Lead sponsor: University of Luebeck
Sponsor class: OTHER
First posted: 2008-02-15
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether immunoadsorption is effective in the treatment of severe atopic dermatitis associated with excessively high serum IgE levels.


Eligibility criteria: Inclusion Criteria:

* Atopical dermatitis
* Total serum IgE level above 5000 kU/l
* IGA score of 3 or above
* No sufficient response to topical corticosteroids/calcineurin inhibitors, UV therapy (at least 4 weeks of therapy), systemic corticosteroids and cyclosporin A (at least 8 weeks of therapy) or no possibility of a prolonged use of this therapy due to adverse events/contraindications
* 18 years of age or above
* Effective contraception during therapy
* Informed consent

Exclusion Criteria:

* Unfavorable conditions for peripheral venous access
* Known hypersensitivity or allergy towards materials used in the adsorber columns
* Adequate anticoagulation not possible (e.g. multiple allergies towards various anticoagulants)
* Extreme bleeding tendency during anticoagulation
* Hypercoagulability
* Severe cardiovascular disease forbidding extracorporeal circulation
* Severe systemic infection
* Serum IgG level below 250 mg/dl
* Severe immunodeficiency (e.g. AIDS)
* Treatment with an ACE inhibitor (discontinue drug at least 72 h before treatment)
* Pregnancy
* Lactation
* A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism or mental dysfunction)

Primary outcomes:
measure: Evidence of clinical improvement of skin condition, pruritus and sleep disturbance.
timeFrame: 13 weeks
Secondary outcomes:
measure: Evidence of reduction of concomitant topical and/or systemic medication.
timeFrame: 13 weeks
Other outcomes:
Locations:
city: Lübeck
country: Germany
facility: Department of Dermatology, University of Lübeck
state: Schleswig-Holstein
Study officials:
affiliation: Department of Dermatology, University of Lübeck, Germany
name: Detlef Zillikens, M. D.
role: STUDY_CHAIR
References:
Clinical trial NCT00122096: Perioperative Inflammation and Cyclooxygenase 2 (COX-2)
Official title: Preoperative Valdecoxib: CNS Penetration and Effects on Biochemical Markers of Pain and Sensitization
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Neurosurgery
Pain
Keywords: neurosurgery
COX-2
inflammation
pain
Lead sponsor: University of Washington
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2005-07-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Surgery initiates a complex cascade of events involving the release of chemical compounds from nerve endings and damaged tissue which leads to an inflammatory and pain response. The purpose of this investigation is to measure various chemical mediators in the blood and cerebrospinal fluid, and to test the hypothesis that they will be decreased in patients treated with a COX-2 inhibitor.

Detailed description: Surgery initiates a complex cascade of events involving the release of nociceptive compounds from nerve endings and damaged tissue which leads to an inflammatory and hyperalgesic response. COX-2 inhibitors are often used for treating pain. This is a double-blind randomized study in surgical patients receiving a spinal drain for surgical purposes. The hypothesis is that valdecoxib will reach therapeutic concentrations in CSF, and will decrease plasma and CSF concentrations of inflammatory mediators. Subjects will receive valdecoxib 40 mg or placebo approximately 1 hr prior to surgery. Serial blood and CSF samples will be obtained. Valdecoxib and cytokine concentrations will be measured.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing surgery requiring lumbar drain placement

Exclusion Criteria:

* Contraindication to COX-2 inhibitor (renal or hepatic insufficiency)
* Known adverse reaction to nonsteroidal anti-inflammatory drugs (NSAIDs)
* Use of NSAID or COX-2 within 7 days prior to surgery

Primary outcomes:
measure: Cerebrospinal fluid (CSF) valdecoxib concentration
Secondary outcomes:
measure: Plasma valdecoxib concentration
measure: CSF/plasma valdecoxib concentration ratio
measure: CSF and plasma cytokine concentrations
measure: Postoperative opioid consumption
measure: Pain visual analogue scale (VAS) scores
Other outcomes:
Locations:
city: Seattle
country: United States
facility: University of Washington
state: Washington
Study officials:
affiliation: Washington University School of Medicine
name: Evan Kharasch, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00838396: A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
Official title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: GERD
Lead sponsor: Indivior Inc.
Sponsor class: INDUSTRY
First posted: 2009-02-06
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.


Eligibility criteria: Inclusion Criteria:

1. History of GERD symptoms (e.g. heartburn episodes) at least 3 times per week
2. Discontinuation of drugs used to treat GERD (PPIs, H2-blockers) and/or drugs known to cause GERD symptoms (e.g. nonsteroidal anti-inflammatory drugs \[NSAIDs\]) for 7 days prior to baseline (Visit 2);
3. Had greater then or equal to 20 postprandial reflux episodes/2 hours recorded using impedance/pH monitoring during Screening/Baseline period (Visit 2)

Exclusion Criteria:

1. History of gastrointestinal disorders other than GERD that may have significantly affected the assessment of reflux episodes or GERD symptoms (e.g. Barrett's Esophagus, active gastric or duodenal ulcer disease, achalasia, scleroderma, etc.).
2. Medical conditions that could have affected assessments of reflux episodes or GERD symptoms (e.g. history of nausea and/or vomiting, neurologic/psychiatric disorders, cardiac disease \[e.g. angina\], lung disease \[e.g. asthma, cough\], etc.)

Primary outcomes:
measure: The primary efficacy assessment endpoint of this study was the total number of reflux episodes (acid and non-acid) comparing study drug to placebo
timeFrame: 12 hours
Secondary outcomes:
measure: Reflux episodes (acid and non-acid) during each treatment period at various time intervals, dose/exposure to reflux rate relationship, acid reflux events, non-acid reflux events, and GERD symptoms.
timeFrame: 12 hours
Other outcomes:
Locations:
city: Stanford
country: United States
state: California
city: Charleston
country: United States
state: South Carolina
city: Tacoma
country: United States
state: Washington
Study officials:
affiliation: XenoPort, Inc.
name: Jay Huff, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00864396: Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux
Official title: Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux: A Double-Blind, Placebo Controlled, Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Laryngopharyngeal Reflux
Keywords: Laryngopharyngeal reflux
Gastroesophageal reflux disease
GERD
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2009-03-18
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).

Detailed description: Laryngopharyngeal reflux (LPR) is a disorder caused by acid-induced damage to the larynx and pharynx (voice box and throat). The standard care for persons with this disorder is treatment with highly potent anti-acid medications (proton pump inhibitors - Prevacid is one of these. NExium, Aciphex and Prilosec are others). These medications are currently approved by the FDA for the treatment of gastroesophageal reflux disease (GERD). Although the use of these medications in persons with LPR is widely accepted and sanctioned, this research is being done because these medications are not currently approved by the FDA for this use. The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).

Eligibility criteria: Inclusion Criteria:

* patients with a clinical diagnosis of laryngopharyngeal reflux diagnosed by any combination of patient symptoms, physical/endoscopic findings, and 24 hr dual-probe ambulatory pH-testing.
* 18 years of age or older

Exclusion Criteria:

* patients with life-threatening complications of laryngeal, pharyngeal or esophageal cancer, subglottic or tracheal stenosis, laryngeal papilloma, airway compromise
* elite vocal performs with LPR-related dysphonia
* under 18 years of age
* pregnant and/or lactating women
* persons with known hypersensitivity to any component of the formulation
* patients taking theophylline, ketoconazole, ampicillin or digoxin
* persons with hepatic and renal insufficiency

Primary outcomes:
measure: To compare the efficacy of twice daily Lansoprazole 30mg to placebo in the treatment of laryngopharyngeal reflux symptoms and findings.
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis Medical Center
state: California
Study officials:
affiliation: University of California, Davis
name: Peter Belafsky, MD, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00255996: Evaluation Of Linezolid Pk Profile In Burns Patients
Official title: An Open Label Parallel Group Study To Investigate The Pharmacokinetics Of Intravenous Linezolid, An Oxazolidinone, Administered To Healthy Volunteers And Patients With Major Thermal Injuries
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Burns
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2005-11-21
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of linezolid pk profile in burns patients


Eligibility criteria: Inclusion Criteria:

* Subject with a Body Mass Index (BMI) \< 30 kg/m\&#178;. For patient with major thermal injuries, the weight will be collected before the burn ;
* Patients with major thermal injuries \>40% body area including 3rd degree burns with full thickness burns ;
* Patients hospitalized for at least 10 days since their thermal injury occurred ;

Exclusion Criteria:

* Contra-indications to use linezolid as mentioned in the SmPC (Summarized Product Characteristics) : hypersensitivity to linezolid use or to any of its components, non-controlled hypertension, phaeochromocytoma, carcinoid syndrome, hyperthyroidism, bipolar disorders, schizoaffective disorders, acute confused state of mind, pregnancy, and breastfeeding ;
* Drugs metabolised by monoamine oxydase (MAO) should be evaluated for potential drug-to-drug interaction;
* Subject treated by: selective serotonin reuptake inhibitors (Prozac\&#174;, Effexor\&#174;, Ixel\&#174; \&#133;), tricyclic antidepressant (Anafranil\&#174;, Sinequan\&#174;, Surmontil\&#174;, Tofranil\&#174;), 5HT1 receptor agonists (triptan) direct or indirect sympathomimetic (including adrenergic bronchodilator, pseudoephedrine and phenylpropylamine), vasopressor (adrenaline and noradrenaline), dopaminergic drugs (dopamine, dobutamine), phenetidine or buspirone should be evaluated for potential drug-to-drug interaction;

Primary outcomes:
measure: To assess and compare pharmacokinetic parameters of a single dose 1-hour intravenous linezolid (Zyvox) at 600 mg in patients with major thermal injuries (>40% body area) and in healthy volunteers
Secondary outcomes:
measure: To assess and compare tolerability and safety of a single dose of 600mg IV linezolid administered in patients with major thermal injuries (>40% body area) and in healthy volunteers.
Other outcomes:
Locations:
city: Nantes
country: France
facility: Pfizer Investigational Site
city: Paris
country: France
facility: Pfizer Investigational Site
city: Paris
country: France
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06437496: 68Ga-AAZTA-093 PET/CT: First-in-human Study
Official title: 68Ga-AAZTA-093 PET/CT: First-in-human Study in Patients With Prostate Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Malignant Neoplasm of Prostate
Lead sponsor: First Affiliated Hospital of Fujian Medical University
Sponsor class: OTHER
First posted: 2024-05-31
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: 68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with prostate cancer.

Detailed description: Prostate cancer (PCa) is one of the most common malignancies worldwide in men. Prostate specific membrane antigen (PSMA), as known as folate hydrolase I or glutamate carboxypeptidase II, is overexpressed on the cells of prostatic adenocarcinoma. Various low molecular weight radiopharmaceuticals targeting PSMA such as PSMA-11, PSMA-617 for 68Ga- or 177Lu- labeling have been developed. 68Ga-AAZTA-093, a novel radiopharmaceutical targeting PSMA, with the urea fragment of a conjugate that employs the AAZTA chelator for labeling with 68Ga(III). This pilot study was prospectively designed to evaluate the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT and compared with 68Ga-PSMA-11 and 68Ga-PSMA-617 PET/CT in the same group of prostate cancer patients.

Eligibility criteria: Inclusion Criteria:

* confirmed treated or untreated prostate cancer patients;
* 68Ga-AAZTA-093 and 68Ga-PSMA-11/68Ga-PSMA-617 PET/CT within 1 week;
* signed written consent.

Exclusion Criteria:

* known allergy against PSMA;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Primary outcomes:
measure: Safety evaluation
timeFrame: Within 7 days following PET/CT
Secondary outcomes:
measure: Dosimetry data
timeFrame: through study completion, an average of 3 months
Other outcomes:
measure: Diagnostic value
timeFrame: through study completion, an average of 3 months
measure: SUV of tumors
timeFrame: through study completion, an average of 3 months
Locations:
city: Fuzhou
country: China
facility: Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
state: Fujian
Study officials:
References:
Clinical trial NCT02482896: The Lolland-Falster Health Study
Official title: The Lolland-Falster Health Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Impaired Health
Disease
Wellbeing
Mental Disorders
Atherosclerosis
Renal Insufficiency, Chronic
Skin Diseases
Urinary Incontinence
Personality
Coronary Disease
Ear Diseases
Nose Diseases
Pharyngeal Diseases
Chronic Disease
Lead sponsor: Region Sjælland
Sponsor class: OTHER
Collaborators: name: Lolland Municipality, Denmark
name: Guldborgsund Municipality, Denmark
First posted: 2015-06-26
Enrollment: 25000
Sex: ALL
Maximum age (years): 110
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: FAMILY_BASED
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The population of Lolland and Guldborgsund municipalities in Denmark.

Brief summary: The study is a epidemiological, cross-sectional study in a mainly rural area of Denmark in Denmark. Life expectancy is shorter, morbidity is higher, and social problems more prevalent than in the urban areas of the country. The population study aims at examining complexities of environmental, hereditary, lifestyle, and social factors as determinants and predisposing factors for morbidity, health, and quality of life. The study will cover physical, mental, and social dimensions and examine family patterns and subgroups. The study will provide baseline information for later follow-up.


Eligibility criteria: Inclusion Criteria:

* Individuals registered in Lolland or Guldborgsund municipality

Exclusion Criteria:

* Adults with incapacity guardianship
* Incapacity to give informed consent
* Individuals with address protection
* Severe physical immobility
* Non-Danish and Non-English speaking

Primary outcomes:
measure: Health
timeFrame: Cross-sectional, measured once
Secondary outcomes:
measure: Morbidity
timeFrame: Cross-sectional, measured once
measure: Risk factors
timeFrame: Cross-sectional, measured once
Other outcomes:
Locations:
city: Nykøbing Falster
country: Denmark
facility: The Lolland-Falster Health Study
state: Region Sjaelland
Study officials:
affiliation: Region Sjælland
name: Knud Rasmussen, Dr. Med., MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Petersen TL, Brond JC, Kristensen PL, Aadland E, Grontved A, Jepsen R. Resemblance in Physical Activity in Families with Children in Time Segments during the Week: The Lolland-Falster Health Study. Med Sci Sports Exerc. 2021 Nov 1;53(11):2283-2289. doi: 10.1249/MSS.0000000000002718.
citation: Jacobsen KK, Jepsen R, Lembeck MA, Nilsson C, Holm E. Associations between the SHARE frailty phenotype and common frailty characteristics: evidence from a large Danish population study. BMJ Open. 2019 Oct 15;9(10):e032597. doi: 10.1136/bmjopen-2019-032597.
citation: Jepsen R, Egholm CL, Brodersen J, Simonsen E, Grarup J, Cyron A, Ellervik C, Rasmussen K. Lolland-Falster Health Study: Study protocol for a household-based prospective cohort study. Scand J Public Health. 2020 Jun;48(4):382-390. doi: 10.1177/1403494818799613. Epub 2018 Sep 17.
Clinical trial NCT01492296: Endoscopy With Short Fasting
Official title: Safety, Quality and Comfort of Upper Gastrointestinal Endoscopy With Conscious Sedation After Fasting for Two Hours
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Upper Gastrointestinal Symptoms
Lead sponsor: Universidade de Passo Fundo
Sponsor class: OTHER
Collaborators: name: Federal University of Rio Grande do Sul
First posted: 2011-12-14
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Upper gastrointestinal (GI) endoscopy is widely used in the clinical practice. An empty stomach is required to ensure quality and safety. For this reason, endoscopy is conventionally performed after 8 or more hours of fasting, which is potentially related to discomfort to the patients. In recent studies, surgical cholecystectomy has been described to be safe after two hours of fasting on liquids. The aim of this study is to assess safety, quality and comfort of upper GI endoscopy after two hours of fasting.


Eligibility criteria: Inclusion Criteria:

* elective endoscopy

Exclusion Criteria:

* poor clinical condition

Primary outcomes:
measure: safety
timeFrame: 10 min (endoscopy duration)
Secondary outcomes:
measure: quality
timeFrame: 10 min (endoscopy duration)
measure: Endoscopy comfort
timeFrame: 8 hours
Other outcomes:
Locations:
city: Passo Fundo
country: Brazil
facility: Hospital Sao Vicente de Paulo
state: RS
Study officials:
References:
citation: Koeppe AT, Lubini M, Bonadeo NM, Moraes I Jr, Fornari F. Comfort, safety and quality of upper gastrointestinal endoscopy after 2 hours fasting: a randomized controlled trial. BMC Gastroenterol. 2013 Nov 9;13:158. doi: 10.1186/1471-230X-13-158.
Clinical trial NCT05738096: Trigeminal Evoked Responses to Improve Rhizotomy
Official title: Trigeminal Evoked Responses to Improve Rhizotomy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Trigeminal Neuralgia
Rhizotomy
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2023-02-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Trigeminal neuralgia (TGN) is a debilitating pain syndrome where electrical, shock- like jolts of pain affect the face. Trigeminal somatosensory evoked potentials (TSEPs) provide a promising modality for measuring the trigeminal sensory and nociceptive pathway by using peripheral stimulation of the trigeminal nerve (on the skin) and measuring low latency evoked potentials on the scalp (contralateral sensory cortex). While TSEPs have been measured in the past, it is not clear if implementing TSEPs into a routine neurosurgical rhizotomy procedure will be feasible. This is a prospective cohort study examining the feasibility of routinely performing TSEPs during rhizotomies for TGN.


Eligibility criteria: Inclusion Criteria:

* Adults of 18 years or older
* Scheduled to undergo percutaneous rhizotomy for facial pain

Exclusion Criteria:

* For TGN: Facial pain of unclear origin (i.e. not clearly TGN pain) or Rhizotomy procedure canceled
* For Healthy control: Diagnosis or history of facial pain such as TMD or TGN, History of migraine, History of any functional pain disorder: fibromyalgia, IBS, CRPS or Recent chronic pain (within last month)

Primary outcomes:
measure: Feasibility
timeFrame: 3 years
Secondary outcomes:
measure: TSEPS peak to peak amplitude within TGN
timeFrame: 1 day
measure: TSEPS latency within TGN
timeFrame: 1 day
measure: TSEPS peak to peak amplitude between control and TGN patients
timeFrame: 1 day
measure: TSEPS latency between control and TGN patients
timeFrame: 1 day
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: David P Darrow, MD
role: PRINCIPAL_INVESTIGATOR
References: